The effectively early detection and determination of
disease progression of
gastric cancer (GC) are still required. An emerging demand for identifying the novel targets adherent to
cancer cells has been still challenged since those valuable profilings not only could act as for early gastric
tumor discovery but also being potential therapeutic views. We have retrospectively analyzed GC biopsies to identify those specific target
peptides in association with
disease progression. We have detected the
polypeptide by liquid mass technology initiated BIO-HIGH innovational assay technology for
tumor-specific target
peptide identification. We have validated the accessibility and feasibility of multiple target cytotoxic T-lymphocyte for the assessment of potential molecular markers by equally comparing the frequencies of
tumor peptides' loci identified in 138 GC patients. The aim was to separate peripheral blood lymphocytes by density gradient centrifugation and use specific target
peptides in in vitro culture of lymphocytes. The Cell Counting Kit-8 assay was set up to prove the lymphocytes' proliferation stimulated by identified
peptides. Both of GC-specific
peptide and shared
peptide were detected in the peripheral blood, and the frequencies and quantities were correlated with disease status and
cancer differentiation, in which BHGa1510 (78%), BHGa1310 (66%), BHGa0910 (57%), BHGa0310 (54%), BHGa0210 (40%), BHGa0810 (35%), BHGa0110 (33%), and BHGa1410 (30%) were apparently scoped out as high-frequency (HF)
peptides could be potentially specific
tumor markers. Moreover, BHGa1410 was significantly associated with
cancer progression, and BHGa0910 and BHGa0210 were significantly associated with TNM stage. The IHC data have shown that both the HF BHGa1510 and HF BHGa1310 were expressions by 100% in contrast with paracancerous tissues of 40% (p < 0.05) and 33%, respectively (p < 0.05). Those specific
peptide pools could be valued in assessment of advanced
tumor and differential status in GC patients.